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Abstract
Background: The full length Rad51 promoter is highly active in cancer cells but not in normal cells. We therefore set out to
assess whether we could confer this tumor-selectivity to an adenovirus vector.
Methodology/Principal Findings: Expression of an adenovirally-vectored luciferase reporter gene from the Rad51 promoter
was up to 50 fold higher in cancer cells than in normal cells. Further evaluations of a panel of truncated promoter mutants
identified a 447 bp minimal core promoter element that retained the full tumor selectivity and transcriptional activity of the
original promoter, in the context of an adenovirus vector. This core Rad51 promoter was highly active in cancer cells that
lack functional p53, but less active in normal cells and in cancer cell lines with intact p53 function. Exogenous expression of
p53 in a p53 null cell line strongly suppressed activity of the Rad51 core promoter, underscoring the selectivity of this
promoter for p53-deficient cells. Follow-up experiments showed that the p53-dependent suppression of the Rad51 core
promoter was mediated via an indirect, p300 coactivator dependent mechanism. Finally, transduction of target cells with an
adenovirus vector encoding the thymidine kinase gene under transcriptional control of the Rad51 core promoter resulted in
efficient killing of p53 defective cancer cells, but not of normal cells, upon addition of ganciclovir.
Conclusions/Significance: Overall, these experiments demonstrated that a small core domain of the Rad51 promoter can
be used to target selective transgene expression from adenoviral vectors to tumor cells lacking functional p53.
Citation: Fong V, Osterbur M, Capella C, Kim Y-E, Hine C, et al. (2011) Adenoviral Vector Driven by a Minimal Rad51 Promoter Is Selective for p53-Deficient Tumor
Cells. PLoS ONE 6(12): e28714. doi:10.1371/journal.pone.0028714
Editor: Volker Thiel, Kantonal Hospital St. Gallen, Switzerland
Received June 14, 2011; Accepted November 14, 2011; Published December 9, 2011
Copyright:  2011 Fong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: VF is a trainee in the Medical Scientist Training Program, funded by the U.S. National Institutes of Health (NIH) award T32 GM07356. This work was also
supported by NIH awards R21 CA122213 (SD), R01 AG031227, R01 AG27237 (VG) and T32 GM068411 (VF). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stephen_dewhurst@urmc.rochester.edu
Introduction
Specific targeting of therapeutic agents to cancer cells while
avoiding damage to normal tissue has been a long time goal in
cancer research. One method of targeting viral agents has been to
use tumor specific promoters to restrict expression of therapeutic
genes [1,2]. Expression of the DNA repair gene, Rad51, has been
shown to be upregulated in many cancers [3,4,5], especially higher
grade [6,7,8,9] chemoresistant [10] and radioresistant tumors
[11]. The Rad51 protein plays a key role in homologous
recombination [12]. Expression is tightly regulated in normal
cells, with dysregulation leading to genomic instability and possibly
contributing to oncogenesis [13,14,15,16,17].
Recently, Gorbunova and colleagues reported that the full
length Rad51 promoter maintains its cancer specificity when taken
independent of its natural context and showed that it can drive
tumor-selective expression of a reporter gene [18]. This makes the
Rad51 promoter a very attractive candidate for use in anti-cancer
therapies especially when coupled with the efficient transduction
capabilities of viral vectors [19]. We therefore conducted
experiments to examine the feasibility of using the Rad51
promoter to drive tumor-selective expression of a transgene of
interest from an adenovirus vector.
An essential initial objective was to define the minimal Rad51
promoter element that retained the robust transcriptional activity
and tumor selectivity of the intact promoter, since the full length
Rad51 promoter reported by Gorbunova and colleagues is over
6.5 kb in length [18] and exceeds the insert capacity for many
adenoviral vectors [20,21]. Our experiments succeeded in
identifying a minimal core promoter element of approximately
450 bp that retained the full tumor selectivity and transcriptional
activity of the intact promoter. We also found that the Rad51
promoter was more active in cancer cells that lacked functional
p53, compared to cells with normal p53 (including both normal
cells and cancer cells with intact p53 function). We then proceeded
to evaluate the ability of this minimal core promoter to drive
selective expression of the herpes simplex virus type 1 (HSV)
thymidine kinase (TK) gene from an adenoviral vector in p53
defective cancer cells. Our studies showed ganciclovir dependent
killing of transduced p53 defective cells with little effect on normal
cells. These data suggest that the Rad51 core promoter may have
utility in virally vectored gene therapies for p53 defective cancers.
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Determination of the Rad51 core promoter region
Previous attempts to define the minimal Rad51 promoter have
yielded conflicting results and were performed only in a single
osteosarcoma cell line, U2-OS [22,23]. In order to better assess the
differential expression of the Rad51promoter, we generated a
panel of truncated Rad51 promoter mutants (Figure 1), inserted
them upstream of a promoterless luciferase reporter and produced
a series of replication-defective, E1-deleted Ad5 vectors that were
evaluated in a panel of normal and cancer cell lines (Table 1).
As can be seen in Figure 2, maximal promoter strength was
retained by a small DNA region surrounding the transcription
start site (2230/+217). Luciferase activity in cells transduced with
a vector containing this element (Rad51core-luc) was essentially
indistinguishable from that in cells transduced with vectors
containing larger fragments of the Rad51 promoter (Rad51-F6-
luc, 22931/+217; Rad51-D230-luc, 2230/+3564) or the intact
full-length Rad51 promoter (22931/+3564) (Figure 2A). To assess
the selectivity of the promoter elements for the various cell lines,
the luciferase activities for each cell line were normalized to
promoter activity in normal human lung fibroblasts, Wi-38 cells,
which was arbitrarily assigned a value of 1. This analysis
(Figure 2B) confirmed that maximal promoter activity and
promoter selectivity were conferred by the Rad51 core promoter
element (2230/+217). In contrast, the same analysis performed
with a CMV promoter showed little to no tumor specificity.
In order to assess whether Rad51core promoter activity was
correlated with endogenous cellular expression of Rad51 protein,
nuclear extracts from each cell type were isolated and analyzed by
Western blot for Rad51 protein (Information S1). A non-
parametic statistical comparison of Rad51 protein content to
Rad51core promoter activity in each cell line revealed a
statistically significant correlation (Spearman rank correlation
coefficient=0.7, with a p-value=0.04; Information S1).
To test whether this core element could be refined further, we
constructed a series of truncated derivatives of the Rad51core
element (Figure 1C). Analysis of the transcriptional activity of
these constructs revealed that all of them were significantly less
active than the Rad51core element (Figure 3). We therefore
focused subsequent studies on the Rad51core promoter construct.
Rad51 promoter activity is suppressed by p53
During the course of testing the Rad51 promoter truncations,
we observed that the Rad51 promoter appeared to be more active
in cells lacking functional p53, than in cells with intact p53
Figure 1. Rad51 promoter constructs. (A) Diagram of the Rad51 gene and upstream region. All labeled positions are specified relative to the
transcription start site. (B) Diagram of the different Rad51 promoter truncations. (C) Diagram of the truncations of the Rad51 core region. A putative
p53 binding region has been reported at position 2161 to 2117. (D) Diagram of promoter mutations affecting the p53-binding region.
doi:10.1371/journal.pone.0028714.g001
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of 9 cell lines into lines previously reported to have defective or
deleted p53, and those reported to have normal p53 function
(Table 1). The median luciferase activity in cells transduced with
Ad5DE1-Rad51full-luc was 272,000 RLU/20 mg cell lysate for
cells with wild-type p53. In contrast, median promoter activity in
cells lacking functional p53 was 10-fold higher, at 2,790,000
RLU/20 mg cell lysate (Figure 4A). Using a Mann-Whitney
analysis we found that Rad51 promoter activity differed
significantly between the 2 groups (p-value=0.03; Figure 4A).
In order to confirm the inverse relationship between Rad51
promoter activity and p53 function, we transfected a p53-null cell
line, H1299, with a plasmid encoding a p53-GFP fusion protein
and then 12 hrs later transduced the same cells with Ad5DE1-
Rad51core-luc or Ad5DE1-CMV-luc. After a further 24 hours,
the cells were then flow cytometrically sorted into GFP+ and
GFP2 populations, lysed and luciferase activity was measured.
When p53 function was restored to H1299 cells, Rad51core
promoter activity was reduced to less than 15% of its original
activity, while there was no significant change in CMV promoter
activity (Figure 4B). This suggests that p53 has a strong and
selective inhibitory effect on the Rad51core promoter. Additional
experiments overexpressing p53 in HeLa cells yielded similar
results - supporting that this inhibitory effect is not limited to
H1299 cells or p53 null cells (Information S1).
The p53 binding site is not required for tumor-selectivity
of the Rad51 core promoter
It has been reported that the Rad51core promoter contains p53
binding elements within the region 2159/2118 upstream of the
transcription start [24]. To test the effect of this region on
transcriptional activity of Rad51core, we derived a series of
plasmid constructs, including (i) promoter truncations spanning
this element (Figure 1D), and (ii) site-directed mutations or internal
deletions of the binding sites (Figure 1E). We then inserted these
constructs upstream of the promoterless luciferase reporter gene in
our replication-defective Ad5 vector, and tested their transcrip-
tional activity.
We first tested promoter constructs that were truncated either
immediately upstream of the putative p53 binding domain
(Rad51-D161, which contains the p53 binding region) or
immediately downstream of this element (Rad51-D117, which
lacks the p53 binding region) (Figure 1D). These constructs were
introduced into p53-null H1299 cells that were then transfected
with the p53-GFP expression plasmid described above, and
FACS-sorted into GFP+ (p53+) and GFP2 (p532) populations.
The transcriptional activity of both of these Rad51 promoter
elements was suppressed in p53-positive cells (GFP+ in Figure 4C)
not in p53-negative cells (GFP2 in Figure 4C). Thus, the presence
or absence of the p53 binding region within the Rad51 promoter
(2161/2117) had no effect the ability of p53 to inhibit Rad51-
mediated transcription.
We next examined the transcriptional activity of site-directed
mutants of the Rad51 promoter, targeting the p53 binding region.
The Rad51mp53 construct is identical to the Rad51core
promoter, except for mutations to the conserved bases of the
putative p53 binding sites, while the Rad51Dp53 construct
contains a precise deletion of the p53 binding region (2159/
2118) (Figure 1E). Each of these constructs was introduced into a
panel of normal and cancer cell lines, along with the Rad51core
promoter construct. The results (Figure 3) showed that the
transcriptional activity of the Rad51 core element was unaffected
either by mutation (Rad51mp53) or deletion (Rad51dp53) of the
p53 binding region even in cells that expressed functional p53.
Based on these data, and the results presented in Figure 4C, we
conclude that p53 suppresses the transcriptional activity of the
Rad51 promoter through a mechanism that is independent of the
reported p53 binding site [24] within the Rad51 promoter.
Overexpression of p300 relieves p53 mediated repression
of the Rad51core promoter
p300 is a ubiquitous coactivator of transcription that has been
reported to interact with many different transcription factors [25],
including p53 [26]. We therefore hypothesized that p53 might
indirectly affect Rad51 promoter activity through interactions with
p300. To test this prediction, we transfected p53null H1299 cells
Table 1. Description of cell lines used in this study.
Cell Lines Known p53 defect Description Citation
Normal cell lines
Wi-38 None Normal lung fibroblasts [42]
HCA-2 None Foreskin fibroblasts immortalized with hTERT [43]
BJ None Foreskin fibroblasts [45]
MRC-5 None Normal lung fibroblasts [47]
SAEC None Normal Small Airway Epithelial Cells (Clonetics) N/A (Primary cell)
nHeps None Normal human primary hepatocytes (Clonetics) N/A (Primary cell)
Cancer cell lines
A549 None Lung carcinoma [46]
BxPc-3 Mutation Y220C Pancreatic adenocarcinoma [31]
MCF-7 None Breast adenocarcinoma [46]
H1299 p53null Non-small cell lung carcinoma [48]
HeLa Likely degradation by HPV E6 Cervical adenocarcinoma [44]
SF-539 None Glioma [46]
U251 Mutation R273H Glioma [46]
doi:10.1371/journal.pone.0028714.t001
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28714Figure 2. Identification of a core Rad51 promoter element. (A) Luciferase assays measuring Rad51 promoter activity in 9 different cancer and
non-cancer cell lines. Cells were transduced with their respective vectors at a MOI of 100. 24 hours post-infection, cells were lysed and luciferase
activity of the cell lysates measured. Data are presented as mean values of independent experimental triplicates; error bars represent the standard
deviation of the data values. (B) As a measure of tumor specificity, luciferase activity for each construct in each cell type was calculated as a ratio
relative to its activity in normal lung fibroblasts (Wi-38).
doi:10.1371/journal.pone.0028714.g002
Rad51 Targeted Adenoviral Vector
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28714Figure 3. Further truncations of the Rad51 core promoter lead to progressive loss of transcriptional activity, while the reported p53
binding site is not required for tumor selectivity of the Rad51 core promoter. Truncations of the Rad51core promoter were created to
determine if all parts were necessary (see Fig. 1C) and modifications to the Rad51core promoter were constructed to evaluate the contribution of
putative p53 binding sites to promoter activity (see Fig. 1E). The p53 binding sites were either mutated at conserved sites (Rad51mp53) or deleted
(Rad51dp53) (as shown in Fig. 1E). (A) Luciferase assays measuring Rad51 promoter activity in 8 different cancer and non-cancer cell lines. Cells were
transduced with their respective vectors at a MOI of 100. 24 hours post-infection, cells were lysed and luciferase activity of the cell lysates measured.
Data are presented as mean values of independent experimental triplicates; error bars represent the standard deviation of the data values. (B) As a
measure of tumor specificity, luciferase activity for each construct in each cell type was calculated as a ratio relative to its activity in normal lung
fibroblasts (Wi-38).
doi:10.1371/journal.pone.0028714.g003
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amounts of p300 expressing plasmid in the presence or absence of
a plasmid expressing wild-type p53. The GFPflag expressing
plasmid, pCMV-GFPflag, was used to as ‘‘filler’’ to ensure
equivalent quantities of DNA were transfected into each sample.
Successful transfection and expression of p53 and p300 was
confirmed by western blot (Figure 5B). Consistent with the data
presented in Figure 4, expression of p53wt repressed transcrip-
tional activity from the Rad51core promoter. However, overex-
pression of p300 relieved this p53 induced repression, in a dose
dependent manner (Figure 5A). Moreover, when p300 was
overexpressed at very high levels, Rad51core promoter activity
was increased above basal levels (e.g., cotransfection of 2.0 mgo fa
p300 encoding plasmid increased transcriptional activity from the
Rad51core promoter by 5.2-fold; Figure 5A).
Tumor-selective induction of cell death, directed by the
Rad51core promoter
Having defined the core Rad51 promoter, and demonstrated its
regulation by p53, we proceeded to examine whether this DNA
element could be used to selectively drive expression of a cytotoxic
effector protein in p53-defective tumor cells. We constructed an
adenoviral vector encoding HSV thymidine kinase under the
control of the Rad51core promoter (Ad5DE1-Rad51core-TK). A
panel of p53 defective cancer cells and non-cancer cell lines were
transduced with Ad5DE1-Rad51core-TK and an Ad5DE1-CMV-
TK control vector at various moi (0 to 500 pfu/cell). Cells were
simultaneously treated with ganciclovir (GCV) at concentrations
ranging from 0 to 200 mM. The p53-defective cancer cells clearly
demonstrated a GCV dose dependent loss of viability with both
vectors (Figure 6), while the primary cell lines only showed loss of
viability in cultures transduced with the control, CMV-driven,
vector (Figure 7). This is exemplified by the fact that, at an MOI of
50 pfu/cell, Ad5DE1-Rad51core-TK caused almost 60% loss of
viability in H1299 cells (Figure 6) treated with 1 mM GCV, while
treatment of BJ fibroblasts (Figure 7) with 106 more vector and
2006higher concentration of GCV resulted in less than 10% loss
of viability. At these same doses, the control vector (Ad5DE1-
CMV-TK) elicited in a similar ,60% loss of viability in H1299
cells, but a much greater, ,74% loss of viability, in BJ fibroblasts.
Discussion
Two previous attempts to map the minimal Rad51 promoter,
both performed in the U2-OS osteosarcoma cell line, identified
different essential promoter domains: 2204/258 [22] and 2536/
2412 [23]. In this report, we performed a more comprehensive
analysis of the Rad51 promoter in a broad range of cell lines,
including both cancer cells and primary cells. Our experiments
defined a small (447 bp) element from the Rad51 promoter that
supports cancer specific transcriptional activity, and is sufficiently
compact to allow its use in DNA delivery systems where transgene
capacity is limited. We found no evidence for the presence of
strong transcriptional suppressor or enhancer elements flanking
this core element [22].
The broad range of cancers in which the core Rad51 promoter
is active may be explained by its increased activity in cells lacking
Figure 4. p53 suppresses Rad51 promoter expression. (A) Cells with functional p53 have lower Rad51 promoter activity. 9 different cancer and
non-cancer cell lines were grouped by their reported p53 status and transduced with Ad5DE1-Rad51full-luc vector at a MOI of 100. 24 hours post-
infection, cells were lysed and luciferase activity of the cell lysates measured. Each point represents the mean value of independent experimental
triplicates of a cell line. The median value of each group, indicated by the line, was determined to be significantly different by a Mann-Whitney
analysis (p=0.03). (B) Restoring expression of p53 in a p53-/- cell line reduces the activity of the Rad51 core promoter. H1299 cells were transfected
with a plasmid encoding either a p53-GFP fusion protein or GFP flag. 12 hrs post-transfection, the cells were transduced with Ad5DE1-Rad51core-luc
vector or Ad5DE1-CMV-luc at a MOI of 100 pfu/cell. 24 hrs thereafter, the cells were collected and sorted into GFP+ and GFP2 populations via FACS.
The cells were then lysed and luciferase activity measured. Data are presented as mean values of independent experimental triplicates; error bars
represent the standard deviation of the data value. The Rad51 promoter activity in p53 positive and negative cells was significantly different, as
determined by a paired student’s T-test (p=0.005); in contrast, the CMV promoter activity was statistically equivalent in both p53 positive and
negative cells. (C) P53 mediated suppression of Rad51 promoter activity was not dependent on a reported p53 binding region (2161/2117).
Methods were as described in (B), except that cells were transduced with Ad5DE1-Rad51D161-luc vector or Ad5DE1-Rad51D117-luc vector instead of
Ad5DE1-Rad51core-luc (see Fig. 1D for schematic representations of these vectors).
doi:10.1371/journal.pone.0028714.g004
Figure 5. Overexpression of p300/CBP overcomes p53-medi-
ated repression of Rad51 core promoter activity. H1299 cells
were cotransfected with a plasmid expressing luciferase under the
control of the Rad51core promoter, in the presence or absence of
plasmids encoding wild-type p53 or p300. Increasing amounts of the
p300 expression were used (as indicated); the total amount of amount
of transfected plasmid DNA in each reaction was maintained at a
constant 4 mg by adding the necessary amount of irrelevant pCMV-
GFPflag plasmid DNA. (A) 48 hours post transfection, cells were
collected, lysed and transcriptional activity measured by Luciferase
assay. Results shown represent the mean of independent experimental
triplicates; error bars represent the standard deviation of the data. (B)
Western blot analysis was performed to confirm expression of p53 and
p300. 10 mg of total protein from each sample was separated on a 7.5%
polyacrylamide gel, transferred to a nitrocellulose membrane, and
probed for each respective protein using antibodies specific for the
indicated proteins (p300, p53 and b-tubulin as a loading control).
doi:10.1371/journal.pone.0028714.g005
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genes in cancer [27]. Our data show that p53 suppresses the
activity of the Rad51 promoter, and that Rad51 promoter activity
in different cell lines has an inverse relationship to p53 function.
Two exceptions to this trend were noted: A549 cells (where the
Rad51 promoter was highly active) and BxPc-3 cells (where
activity was lower than in other p53-defective cells). We tentatively
attribute this to additional regulatory dysfunction in these cancer
lines. A549 cells have been reported to have an overexpression of
MDM-2 [28], which promotes nuclear export [29] and degrada-
tion of p53 protein [30]. As a consequence, Lu et al. were unable
to detect p53 in A549 cells by immunocytochemical staining, and
they reported low levels of p53 in the cell even after transduction
with exogenous p53 DNA. This suggests that, while the p53 gene
is normal in A549 cells, protein expression levels are extremely low
– and possibly too low to effectively suppress Rad51-driven gene
expression. In the case of the BxPc-3 pancreatic cancer cell line,
we confirmed that the previously described mutation at codon 220
of the p53 gene in this cell line was indeed present [31]. However,
BxPc-3 cells have been shown to express high levels of mutant p53
[3,31]. Thus, one possible explanation for our data is that the
overabundance of this mutant isoform of p53 in BxPc-3 cells
actually serves to further sequester p300 (resulting in low levels of
Rad51-driven luciferase expression). Additionally, pancreatic
cancer cells have been shown to accurately reflect their malignant
phenotype [3], in which Rad51 is overexpressed, only when
cultured in a three dimensional matrix.
Overall, our results are broadly consistent with a previous report
that p53 can suppress the transcriptional activity of the Rad51
promoter [24]. Contrary to this study, however, we found that
p53-mediated suppression of Rad51 promoter activity occurred
independently of the reported p53 binding region in the promoter
[24]. This may reflect methodological differences, since we studied
the core Rad51 promoter (2230/+217) in the context of a linear
adenoviral vector, whereas Arias-Lopez et al. studied a larger
fragment of the promoter (2948/+1427) in the context of a
circular plasmid vector [24]. Regardless, our data strongly suggest
that p53 can act an indirect manner, possibly through effects on
other transcription factors or cofactors that may regulate the
Rad51 promoter.
p300 is a well known co-activator of transcription, shown to
interact with p53 and many other transcription factors [25]. Here
we showed that overexpression of p300 increased transcriptional
activity from the Rad51core promoter and relieved the p53
mediated repression (Figure 5). This suggests that p53 may have
sequestered limiting amounts of p300 that otherwise could have
Figure 6. The Rad51core promoter can be used to selectively express a toxic gene in p53-defective cells. P53 defective cancer cells (as
indicated) were transduced with a replication-defective Ad5 vector encoding the HSV thymidine kinase (TK) gene under the transcriptional control of
the Rad51core element (Ad5DE1-Rad51core-TK) or the constitutively active CMV promoter (Ad5DE1-CMV-TK). Cells were transduced with the vector
at the indicated MOIs (5 or 50), in the presence or absence of varying concentrations of ganciclovir (0–100 mM). Five days later, cell viability was
determined with AlamarBlue
TM dye and normalized as a percentage of the mean value of untreated cells. Data are presented as mean values of
independent experimental triplicates; error bars represent the standard deviation of the data.
doi:10.1371/journal.pone.0028714.g006
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pression increased Rad51core promoter activity even in the
absence of p53 further supports the idea that p300 is limiting with
respect to the transcriptional activity of the Rad51core promoter,
and suggests that some additional inhibitory factors may be acting
on this promoter in a p300-dependent manner.
It has been previously suggested that competition by transcrip-
tion factors for binding to limiting amounts of p300/CBP protein
may lead to transcriptional repression of one of the competing
gene targets [32,33]. Furthermore p53 has been shown to
transcriptionally repress target genes through interaction with
p300/CBP binding partners, such as Ets1/2 [34], Sp1 [35] and
C/EBP [36]. Analysis of the Rad51core promoter using the
Transcription Element Search System (TESS) [37], revealed
potential binding sites for the transcription factors Sp1, C/EBP,
and E2F-1. Hasselbach et al. also reported binding sites and DNA
binding by E2F-1 as well as by STAT-5 within the Rad51
promoter [22], and Rad51 expression has been shown to be
regulated by E2F-1 [38] and STAT5 [39]. Since all of these
transcription factors can be activated through interactions with
p300/CBP [25,40], competitive binding of p53 to p300/CBP
offers a likely mechanism through which p53 may repress the
Rad51 core promoter. Alternatively Rad51 may be also regulated
by the many changes to cellular metabolism that occur during
oncogenic transformation, some of which may be the result of a
p53 defect.
Finally, we demonstrated the ability of a Rad51core driven
adenoviral vector to achieve selective cell killing of p53-defective
cancer cells (Figure 6), while sparing normal cells (Figure 7). The
Ad5DE1-Rad51core-TK and Ad5DE1-CMV-TK vectors were
Figure 7. Expression of a toxic gene from the Rad51core promoter causes little toxicity in primary cells. Primary cells (as indicated) were
transduced with high doses of a replication-defective Ad5 vector encoding the HSV TK gene under the transcriptional control of the Rad51core
element (Ad5DE1-Rad51core-TK) or the constitutively active CMV promoter (Ad5DE1-CMV-TK). Cells were transduced with the vector at the indicated
MOIs (5–500), in the presence or absence of varying concentrations of ganciclovir (0–200 mM). Five days later, cell viability was determined with
AlamarBlue
TM dye and normalized as a percentage of the mean value of untreated cells. Data are presented as mean values of independent
experimental triplicates; error bars represent the standard deviation of the data.
doi:10.1371/journal.pone.0028714.g007
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defective cancer cells. This demonstrates the robust ability of the
Rad51 promoter to drive expression of a cytotoxic transgene in
cancer cells. Moreover the Ad5DE1-Rad51core-TK vector was
not cytotoxic to normal cell lines, whereas the Ad5DE1-CMV-TK
vector elicited GCV-dependent cell death even in normal cells.
The toxicity of the CMV-driven vector demonstrates that
adenoviral vectors can efficiently transduce normal cells, under-
scoring the selectivity and potential utility of the Rad51 promoter.
The efficacy with which the vector killed p53-defective tumor cells
was correlated with the transcriptional activity of the Rad51core
promoter in the various cells. Overall, these data establish proof of
principle support for the use of the Rad51core promoter in virally
vectored gene therapies for p53 defective cancers.
Materials and Methods
Cell culture
HEK 293A [41], Wi-38 [42], HCA-2 [43], Hela [44], BJ [45],
MCF-7 [46], A549 [46] and MRC-5 [47] cells were cultured in
Dulbecco’s Modified Eagle Medium (Gibco) supplemented with
10% FBS (Gibco) and 16 Pen Strep Glutamine (Gibco). H1299
[48], BxPc-3 [31], U251 [46], SF-539 [46] cells were cultured in
RPMI 1640 medium (Gibco) supplemented with 10% FBS (Gibco)
and 16Pen Strep Glutamine (Gibco). SAEC (Lonza) and nHeps
(Lonza) cells were cultured in the growth media suggested by the
vendor.
Cloning of Rad51 promoters
The Rad51full promoter was PCR amplified from human
genomic DNA and cloned into peGFP (Clontech) as described
[18]. All subsequent truncations were made by PCR or restriction
enzyme digestion from peGFP-Rad51full. Rad51-mp53 and
Rad51-Dp53 were commercially synthesized by GeneArt (Regens-
burg, Germany). Rad51-mp53 is derived from Rad51core and has
the underlined nucleotides in the region 2159/2118 mutated
from AAACTCGCGCAGGATCAAGCTCTCGAGCTCCCG-
TCTTGGGT to AAAGGCCCGCAGGATGGCCCTCTCGA-
GCTCCCGTGGCCGGT. Rad51-Dp53 is also derived from
Rad51core but has the entire region deleted.
Virus construction
All adenovirus vectors were made with the AdEasy
TM system
(Stratagene). Rad51 promoter constructs were cloned upstream of
a luciferase cassette in a pShuttle backbone, recombined with
pAdEasy and linearized to form an adenoviral genome. This DNA
was transfected into HEK 293A cells for virus production and
amplification. Viruses were collected, purified on a CsCl gradient
and titered by plaque assay. A control vector expressing luciferase
and GFP from the constitutive CMV promoter, Ad5DE1-CMV-
GFPluc, was created by cloning the luciferase gene from pGL3-
basic into the pAdtrack shuttle plasmid and recombined into
pAdeasy; virus production was then completed as described above.
A control vector that expressed only luciferase under the control of
the CMV promoter, Ad5DE1-CMV-luc, was purchased from
Vector Biolabs (Philadelphia, PA).
Measuring promoter activity
Each cell type was seeded at a density of 5610
5 cells per well
into 6-well plates and cultured overnight. The following morning,
the cell culture media was removed and replaced with fresh media
containing the indicated adenoviral vectors at a multiplicity of
infection (MOI) of 100 pfu/cell. 24 hours after transduction the
cells were collected and lysed with Passive Lysis Buffer (Promega).
Luciferase assays were performed with Luciferase Assay System
from Promega and luminescence measured on a DTX880
multimode plate reader (Beckman Coulter). All samples were
normalized by total protein content as determined by Bradford
assay.
p53 rescue experiment
1610
6 H1299 cells were seeded in 30 mm cell culture plates
and cultured overnight. The following morning, 4.0 mg of either
pEGFP-p53 or pCMV-GFPflag was transfected into the cells using
Lipofectamine2000 (Invitrogen). 12 hrs post-transfection, the cells
were infected with Ad5DE1-Rad51core-luc or Ad5DE1-CMV-luc
at an MOI of 100. 24 hrs post-infection, the cells were collected
and sorted into GFP+ and GFP2 populations on a FACSAriaII
cell sorter. The cells were then lysed and luciferase activity
measured with the Luciferase Assay System from Promega,
described above. The experiment presented in Information S1,
using HeLa cells, was performed using essentially methods.
Co-activator overexpression experiments
H1299 cells were seeded in 6-well plates at a density of 2.5610
5
cells/well. The following day cells were cotransfected with a
plasmid expressing luciferase under the control of Rad51core
promoter (1 mg pShuttle-Rad51core-luc), in the presence or
absence of plasmids expressing p53wt (1 mg pCMV-p53wt), p300
(0.5–2 mg pCMV-p300) and GFPflag (pCMV-GFPflag) using
Lipofectamine2000 (Invitrogen). The amount of irrelevant
GFPflag plasmid (‘‘filler’’) DNA was adjusted to maintain a total
of 4 mg transfected DNA in all conditions. 6 hours post
transfection, the serum free transfection medium was replaced
with fresh culture medium and cell were then incubated for
48 hours at 37u prior to collection, lysis and performance of
luciferase assays, as described above.
GCV/HSVtk treatment and cell viability measurement
Cells were seeded in 96-well plates at a density of 1610
3 cells
per well. 24 hours later, culture media was aspirated and replaced
with fresh media containing appropriate dilutions of ganciclovir
and vector. The cells were returned to incubate at 37u C for 5 days
after which cells were stained with AlamarBlue
TM (Invitrogen).
Cell culture media was removed from cells, replaced with fresh
media + AlamarBlue
TM, and cells were then incubated at 37uC for
an additional 12 hours. Fluorescence (EX=535 nm, EM=
595 nm) was measured in a DTX880 multimode plate reader
(Beckman Coulter). Cell viability was calculated as a percentage of
the mean value of untreated cells.
Supporting Information
Information S1 Rad51core promoter activity correlates
with host cell expression of Rad51 protein. (A) Nuclear
extracts were isolated from each cell type and 3 mg of total protein
was separated on a 10% polyacrylamide gel, transferred to a
nitrocellulose membrane, and probed with a monoclonal antibody
for Rad51. The blots were stripped and re-probed for b-tubulin as
a loading control. All displayed samples were run on the same blot.
(B) Rad51 expression was quantitated by densitometry from the
blot shown in panel (A) using QuantityOne software (BioRad);
Rad51 expression was then normalized in terms of housekeeping
protein levels (b-tubulin). Rad51 expression levels in normal
fibroblasts (Wi-38 cells) were defined as 1, and Rad51 expression
levels in the other cells were then expressed relative to this. Shown
is a scatterplot of endogenous Rad51 protein content for each cell
line, versus the level of Rad51core promoter activity in the same
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test and determined to be significant (Spearman rank correlation
coefficient=0.7, p=0.04).
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